Crinetics Pharmaceuticals received FDA approval for Palsonify (paltusotine), the first oral first-line therapy for adults with acromegaly, a rare hormonal disorder characterized by excessive growth hormone production. This once-daily pill offers a non-injection alternative to existing treatments from Novartis and Ipsen. Clinical trials demonstrated significant reductions in growth hormone levels with a favorable safety profile. This marks Crinetics’ entry into a market dominated by injectable therapies, potentially reshaping acromegaly management.